Are Metastases from Metastases Clinical Relevant? Computer Modelling of Cancer Spread in a Case of Hepatocellular Carcinoma

Background Metastasis formation remains an enigmatic process and one of the main questions recently asked is whether metastases are able to generate further metastases. Different models have been proposed to answer this question; however, their clinical significance remains unclear. Therefore a computer model was developed that permits comparison of the different models quantitatively with clinical data and that additionally predicts the outcome of treatment interventions. Methods The computer model is based on discrete events simulation approach. On the basis of a case from an untreated patient with hepatocellular carcinoma and its multiple metastases in the liver, it was evaluated whether metastases are able to metastasise and in particular if late disseminated tumour cells are still capable to form metastases. Additionally, the resection of the primary tumour was simulated. The simulation results were compared with clinical data. Results The simulation results reveal that the number of metastases varies significantly between scenarios where metastases metastasise and scenarios where they do not. In contrast, the total tumour mass is nearly unaffected by the two different modes of metastasis formation. Furthermore, the results provide evidence that metastasis formation is an early event and that late disseminated tumour cells are still capable of forming metastases. Simulations also allow estimating how the resection of the primary tumour delays the patient's death. Conclusion The simulation results indicate that for this particular case of a hepatocellular carcinoma late metastases, i.e., metastases from metastases, are irrelevant in terms of total tumour mass. Hence metastases seeded from metastases are clinically irrelevant in our model system. Only the first metastases seeded from the primary tumour contribute significantly to the tumour burden and thus cause the patient's death.

[1]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[2]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[3]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[4]  Mauro Ferrari,et al.  Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation , 2008, Journal of mathematical biology.

[5]  Donald E Ingber,et al.  A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. , 2006, Breast disease.

[6]  C. Beck,et al.  A superstatistical model of metastasis and cancer survival , 2007, 0711.4687.

[7]  K. Pavelić,et al.  Metastasis: new perspectives on an old problem , 2011, Molecular Cancer.

[8]  Assia Benabdallah,et al.  Mathematical and numerical analysis for a model of growing metastatic tumors. , 2009, Mathematical biosciences.

[9]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[10]  T. Suda,et al.  Cancer stem cells and their niche , 2009, Cancer science.

[11]  M. Manns,et al.  Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients , 2005, British Journal of Cancer.

[12]  O. Salazar,et al.  Breast Cancer: Metastatic Patterns and Their Prognosis , 1988, Southern medical journal.

[13]  N. Tabibian Hepatocellular carcinoma in the United States. , 1988, American family physician.

[14]  R. Jenkins,et al.  Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival , 1996, Cancer.

[15]  N. Shigesada,et al.  A dynamical model for the growth and size distribution of multiple metastatic tumors. , 2000, Journal of theoretical biology.

[16]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[17]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[18]  R. Bresalier,et al.  The Biology of Cancer. Garland Science, Oxford, UK (2006), 864 pp. $104.95, ISBN: 0-8153-4076-1. Web site for ordering: www.garandscience.com , 2007 .

[19]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[20]  Fernando Pons,et al.  Staging systems in hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[21]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[22]  C. Rossi,et al.  Distant metastases in ovarian carcinoma , 2002, International Journal of Gynecologic Cancer.

[23]  Antje Walz,et al.  Modeling of tumor growth and anticancer effects of combination therapy , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[25]  R. Fodde,et al.  Cancer stemness and metastasis: therapeutic consequences and perspectives. , 2010, European journal of cancer.

[26]  Barbara L. Smith,et al.  Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death , 2009, Cancer.

[27]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[29]  Barbara L. Smith,et al.  How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death , 2009, Cancer.

[30]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[31]  J. Gschwend,et al.  Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. , 2010, European urology.

[32]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[33]  Eva Forssell-Aronsson,et al.  Model of metastatic growth valuable for radionuclide therapy. , 2003, Medical physics.

[34]  N. Stoecklein,et al.  Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis , 2010, International journal of cancer.